Bookmarks
VinCaP
Population Size
Not reported
Years
2016
Associated BioSamples
Tissue
Geographic coverage
United Kingdom
England
Lead time
Other
Summary
Collection of samples and data across the following diseases: Malignant tumour of penis (disorder)
Documentation
VinCaP is a phase II, multicentre, non-randomised trial of Vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the Penis. 22 evaluable participants will be recruited from 9 centres and all patients will receive 4 cycles of IV vinflunine 320mg/m2 on day 1, to be repeated at intervals of 21 days. The primary endpoint, determined by RECIST v1.1, is clinical benefit (objective response + stable disease rate) measured after four cycles of vinflunine chemotherapy. Secondary endpoints are objective response rate (CR+PR), toxicity, progression-free survival, overall survival and treatment compliance. Formalin fixed paraffin embedded (FFPE) tumour blocks are held at the Orchid Tissue Laboratory and Barts and The London School of Medicine and Dentistry.
Dataset type
Health and disease
Dataset sub-type
Not applicable
Keywords
Provenance
Image contrast
Not stated
Biological sample availability
Tissue
Details
Publishing frequency
Other
Version
1.0.0
Modified
08/10/2024
Citation Requirements
In Progress
Coverage
Start date
01/01/2016
Time lag
Variable
Geographic coverage
United Kingdom, England
Minimum age range
40
Maximum age range
150
Accessibility
Language
en
Controlled vocabulary
LOCAL
Format
In Progress
Data Access Request
Dataset pipeline status
Not available
Access rights
Please contact the publisher using Contact Point details provided
Time to dataset access
Other
Access request cost
Not specified
Access method category
Varies based on project
Data Controller
The Institute of Cancer Research